不稳定性心绞痛患者血小板聚集率与主要心血管不良事件发生的相关性

摘要/Abstract

摘要： 目的探讨与分析不稳定性心绞痛（unstable angina）患者血小板聚集率（platelet aggregation rate,PAR）与主要心血管不良事件（major cardiovascular adverse events,MACE）发生的相关性。方法选择2021年5月—2022年7月在新疆生产建设兵团第二师库尔勒医院住院的134例不稳定性心绞痛患者为研究对象,检测所有患者入院时的血小板聚集率,随访患者的主要心血管不良事件发生情况并进行相关性分析。结果所有患者随访到2023年5月1日,平均随访时间为（24.10±1.93）个月,发生主要心血管不良事件21例（MACE组）,占15.7%,其中心肌梗死3例、心源性死亡1例、心力衰竭4例、支架内血栓形成13例。MACE组的性别、年龄、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、收缩压、舒张压、吸烟、饮酒等与非MACE组比较,差异无统计学意义（P>0.05）。两组的血小板计数、血小板分布宽度、平均血小板体积、血小板压积等比较,差异无统计学意义（P<0.05）。MACE组的血小板聚集率较非MACE组明显增高,差异有统计学意义（P<0.05）。在134例患者中,Spearman相关性分析显示血小板聚集率与主要心血管不良事件的发生存在相关性（r=0.724,P<0.001）。多因素Logistic回归分析显示,血小板聚集率为导致不稳定性心绞痛患者随访发生主要心血管不良事件的重要因素（P<0.05）。结论不稳定性心绞痛患者的主要心血管不良事件发生率比较高,主要心血管不良事件的发生多伴随血小板聚集率增高,不稳定性心绞痛患者血小板聚集率与主要心血管不良事件的发生存在相关性。

关键词: 不稳定性心绞痛, 主要心血管不良事件, 血小板聚集率, 相关性, 低密度脂蛋白胆固醇, 支架内血栓

Abstract: Objective To explore and analysis the correlation between platelet aggregation rate (PAR) and major cardiovascular adverse events (MACE) in patients with unstable angina. Methods From May 2021 to July 2022, 134 cases of patients with unstable angina who were hospitalized in the cardiovascular department of Kulle Hospital, Second Division, Xinjiang Production and Construction Corps were selected as the research subjects. The platelet aggregation rate of all patients at admission was measured, and the main cardiovascular adverse events of the patients were followed up and were give correlation analysis. Results All patients were followed up until May 1, 2023, with an average follow-up time of (24.10 ±1.93) months. There were 21 cases of major cardiovascular adverse events (MACE group) that accounted for 15.7%, included 3 cases of myocardial infarction, 1 case of cardiac death, 4 cases of heart failure, and 13 cases of stent thrombosis. There were no significant difference in sex, age, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, systolic blood pressure, diastolic blood pressure, smoking, alcohol consumption compared between the MACE group and the non MACE group (P>0.05). There were no significant difference in platelet count, platelet distribution width, average platelet volume, and platelet hematocrit compared between the two groups (P<0.05). The platelet aggregation rate in the MACE group were significantly higher than that in the non MACE group (P<0.05). In the 134 patients, Spearman correlation analysis showed a correlation between platelet aggregation rate and the occurrence of major cardiovascular adverse events (r=0.724, P<0.001). Multivariate logistic regression analysis showed that platelet aggregation rate was an important factor leading to major cardiovascular adverse events in patients with unstable angina during follow-up (P<0.05). Conclusion The incidence of major cardiovascular adverse events in patients with unstable angina is relatively high, and the occurrence of major cardiovascular adverse events is often accompanied by an increase in platelet aggregation rate. There is a correlation between platelet aggregation rate and the occurrence of major cardiovascular adverse events in patients with unstable angina.

Key words: unstable angina pectoris, major cardiovascular adverse events, platelet aggregation rate, relevance, low density lipoprotein cholesterol, intrastent thrombosis

中图分类号:

R541

陈海宏, 王继伟, 刘一鸣. 不稳定性心绞痛患者血小板聚集率与主要心血管不良事件发生的相关性[J]. 中华养生保健, 2024, 42(5): 12-15.

CHEN Hai-hong, WANG Ji-wei, LIU Yi-ming. The Correlation Between Platelet Aggregation Rate and Major Cardiovascular Adverse Events in Patients with Unstable Angina Pectoris[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(5): 12-15.

参考文献

[1] 张娟,武佶,魏希进,等.参芪丹鸡黄精汤加减联合西药治疗冠状动脉慢性完全闭塞病变患者的临床效果[J].中国医药,2023,18(4):578-582.
[2] 杨世磊,李璐,朱艳娜,等.仿制与原研替格瑞洛抗血小板治疗有效性和安全性的比较研究[J].药物不良反应杂志,2023,25(3):145-151.
[3] 李兰霞,王东雁,王蒙,等.红景天注射液与芪苈强心胶囊对冠心病心绞痛患者抗氧化应激指标及心功能的影响[J].中国中西医结合急救杂志,2022,29(1):53-56.
[4] 李映智,廖莹峰.参麦注射液联合长效硝酸异山梨酯对冠心病心绞痛患者疗效及对血小板聚集率的影响[J].血栓与止血学,2022,28(1):52-53.
[5] 周勇,周争光,施龙.替格瑞洛联合低分子肝素对老年不稳定型心绞痛PCI术后的疗效[J].中国老年学杂志,2022,42(20):4928-4930.
[6] 王丽,张立平,任玉娇,等.极重度替罗非班相关血小板减少症临床病例分析[J].药物不良反应杂志,2022,24(9):471-477.
[7] 苏凯杰,王晓晓,唐雯.腹膜透析置管术围手术期应用抗凝或抗血小板药物对出血及心脑血管事件的影响[J].中华肾脏病杂志,2022,38(4):320-328.
[8] 雷玲. 美国“不稳定型心绞痛和非ST段抬高心肌梗死治疗指南”更新[J].世界临床药物,2012,33(8):511.
[9] 李妍,李红,王艳.润肺解毒汤加减对冠心病心绞痛气滞血瘀证病人血清PAPP-A及VASP的影响[J].中西医结合心脑血管病杂志,2022,20(4):592-596.
[10] 邹国良,张蕾蕾.加味养心汤治疗不稳定型心绞痛的临床疗效及对血小板聚集率、血浆纤维蛋白原的影响[J].现代中西医结合杂志,2022,31(15):2130-2134.
[11] 俸道荣,韦斌,曲楠,等.瓜蒌薤白半夏汤合小建中汤加减治疗阳虚痰阻型稳定型心绞痛的临床研究[J].中华中医药杂志,2022,37(2):1184-1187.
[12] 王旺,史波,叶小彬,等.黄芪桂枝五物汤加味对NSTE-ACS患者PCI术后NLR、hs-CRP、LP(α)的影响研究[J].中国中医急症,2022,31(6):1080-1082.
[13] 申剑峰,王海红.参麦注射液联合长效硝酸异山梨酯对冠心病心绞痛患者疗效及对血小板聚集率的影响分析[J].贵州医药,2022,46(11):1794-1796.
[14] 李宁,陈晓杰,李金宝,等.益气活血方对急性心肌梗死术后气虚血瘀证患者血小板聚集及心室重构的影响[J].现代中西医结合杂志,2022,31(11):1554-1557.
[15] 张以昆,韩景波,王庆高,等.化痰开痹汤对冠心病心绞痛痰浊痹阻型病人血栓前状态及血小板聚集率的影响[J].中西医结合心脑血管病杂志,2022,20(10):1732-1735.
[16] 李建民,张景昌,黄学成,等.CYP2C19基因检测指导冠心病患者氯吡格雷精准用药研究[J].医药论坛杂志,2022,43(20):83-85.
[17] 白丽娜,张虹,严萍,等.心可舒治疗冠心病心绞痛的疗效及对血液流变学及炎症因子的影响——一项多中心、随机、双盲、安慰剂对照临床研究[J].实用药物与临床,2021,24(8):678-683.
[18] 崔志红,林雪芳,姚根琴,等.吲哚布芬与阿司匹林治疗急性冠状动脉综合征有效性及安全性比较的Meta分析[J].浙江医学,2022,44(9):974-979.
[19] 王悦,王志强,刘倍倍,等.不稳定型心绞痛患者经皮冠状动脉介入术后长期应用小剂量替格瑞洛的抗凝疗效分析[J].心肺血管病杂志,2021,40(1):6-11.
[20] 李建朝,钱晓亮,任培军,等.大株红景天注射液结合瑞舒伐他汀对不稳定型心绞痛疗效及心功能影响研究[J].中华中医药学刊,2021,39(6):209-212.
[21] 史明帅. 氯吡格雷联合阿司匹林对稳定型心绞痛合并糖尿病患者血小板聚集率及FIB水平的影响[J].现代诊断与治疗,2021,32(4):521-522.